Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Morfini

Showing results (31-40 of 151) with videos related to

Pageof 16
Sort By:
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 8, 2012
Surgical treatment of a complete symptomatic ossification of quadratus femoris muscle in a young haemophilic patientC Carulli, R Civinini, F Matassi, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|October 3, 2014
Pharmacokinetics of plasma-derived vs. recombinant FVIII concentrates: a comparative studyM Morfini, E Marchesini, E Paladino, et al.
The International Journal of Artificial Organs|May 1, 1988
Aspects of biocompatibility of two different dialysis membranes: cuprophane and polysulfoneM Amato, M Salvadori, F Bergesio, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|January 10, 2012
Cord blood hematopoietic stem cell transplantation in an adolescent with haemophiliaD Caselli, M Morfini, O Paolicchi, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|August 25, 2010
Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophiliaP W Collins, K Fischer, M Morfini, et al.
Thrombosis and Haemostasis|October 5, 1992
Pharmacokinetic properties of recombinant factor VIII compared with a monoclonally purified concentrate (Hemofil M). The Recombinate Study GroupM Morfini, G Longo, A Messori, et al.
Transfusion|April 1, 1995
Comparison of the recovery and half-life of a high-purity factor IX concentrate with those of a factor IX complex concentrate. Factor IX Study GroupM C Poon, L M Aledort, K Anderle, et al.
Thrombosis and Haemostasis|August 28, 2002
Reduced activation of the Gla19Ala FX variant via the extrinsic coagulation pathway results in symptomatic CRMred FX deficiencyM Pinotti, G Marchetti, M Baroni, et al.
Journal of Medical Virology|June 1, 1988
Human parvovirus infection in haemophiliacs first infused with treated clotting factor concentratesO Bartolomei Corsi, A Azzi, M Morfini, et al.
Haematologica|July 17, 2001
Multivariate analysis of factors influencing quality of life and utility in patients with haemophiliaS Trippoli, M Vaiani, S Linari, et al.
Pageof 16

Showing results (31-40 of 151) with videos related to

Sort By:
Pageof 16
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 8, 2012
Surgical treatment of a complete symptomatic ossification of quadratus femoris muscle in a young haemophilic patientC Carulli, R Civinini, F Matassi, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|October 3, 2014
Pharmacokinetics of plasma-derived vs. recombinant FVIII concentrates: a comparative studyM Morfini, E Marchesini, E Paladino, et al.
The International Journal of Artificial Organs|May 1, 1988
Aspects of biocompatibility of two different dialysis membranes: cuprophane and polysulfoneM Amato, M Salvadori, F Bergesio, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|January 10, 2012
Cord blood hematopoietic stem cell transplantation in an adolescent with haemophiliaD Caselli, M Morfini, O Paolicchi, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|August 25, 2010
Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophiliaP W Collins, K Fischer, M Morfini, et al.
Thrombosis and Haemostasis|October 5, 1992
Pharmacokinetic properties of recombinant factor VIII compared with a monoclonally purified concentrate (Hemofil M). The Recombinate Study GroupM Morfini, G Longo, A Messori, et al.
Transfusion|April 1, 1995
Comparison of the recovery and half-life of a high-purity factor IX concentrate with those of a factor IX complex concentrate. Factor IX Study GroupM C Poon, L M Aledort, K Anderle, et al.
Thrombosis and Haemostasis|August 28, 2002
Reduced activation of the Gla19Ala FX variant via the extrinsic coagulation pathway results in symptomatic CRMred FX deficiencyM Pinotti, G Marchetti, M Baroni, et al.
Journal of Medical Virology|June 1, 1988
Human parvovirus infection in haemophiliacs first infused with treated clotting factor concentratesO Bartolomei Corsi, A Azzi, M Morfini, et al.
Haematologica|July 17, 2001
Multivariate analysis of factors influencing quality of life and utility in patients with haemophiliaS Trippoli, M Vaiani, S Linari, et al.
Pageof 16